PubMed

A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.

Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P.

Diabetes Care. 2006 Jun;29(6):1269-74. Erratum in: Diabetes Care. 2007 Apr;30(4):1035. PMID: 16732007 [PubMed - indexed for MEDLINE]Related articlesFree article

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.

Standl E, Lang H, Roberts A.

Diabetes Technol Ther. 2004 Oct;6(5):579-88.PMID: 15628811 [PubMed - indexed for MEDLINE]Related articles

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.

Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G.

Diabetologia. 2008 Mar;51(3):408-16. Epub 2008 Jan 16.PMID: 18204830 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.

Clin Ther. 2004 May;26(5):724-36.PMID: 15220016 [PubMed - indexed for MEDLINE]Related articles

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.

Hollander P, Cooper J, Bregnhøj J, Pedersen CB.

Clin Ther. 2008 Nov;30(11):1976-87.PMID: 19108786 [PubMed - indexed for MEDLINE]Related articles

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group.

Diabetes Care. 2004 May;27(5):1081-7.PMID: 15111525 [PubMed - indexed for MEDLINE]Related articlesFree article

Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.

Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.

Diabet Med. 2008 Aug;25(8):916-23.PMID: 18959604 [PubMed - indexed for MEDLINE]Related articles

Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.

Davies MJ, Derezinski T, Pedersen CB, Clauson P.

Diabetes Technol Ther. 2008 Aug;10(4):273-7.PMID: 18715200 [PubMed - indexed for MEDLINE]Related articles

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes.

Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B.

Clin Ther. 2006 Oct;28(10):1569-81. Erratum in: Clin Ther. 2006 Nov;28(11):1967. PMID: 17157113 [PubMed - indexed for MEDLINE]Related articles

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

Yki-Järvinen H, Dressler A, Ziemen M; HOE 901/300s Study Group.

Diabetes Care. 2000 Aug;23(8):1130-6.PMID: 10937510 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.

Bartley PC, Bogoev M, Larsen J, Philotheou A.

Diabet Med. 2008 Apr;25(4):442-9.PMID: 18387078 [PubMed - indexed for MEDLINE]Related articlesFree article

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators.

Diabetes Care. 2003 Nov;26(11):3080-6.PMID: 14578243 [PubMed - indexed for MEDLINE]Related articlesFree article

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.

Kølendorf K, Ross GP, Pavlic-Renar I, Perriello G, Philotheou A, Jendle J, Gall MA, Heller SR.

Diabet Med. 2006 Jul;23(7):729-35.PMID: 16842476 [PubMed - indexed for MEDLINE]Related articles

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB.

Diabetes Care. 2001 Apr;24(4):631-6.PMID: 11315821 [PubMed - indexed for MEDLINE]Related articlesFree article

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.

Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.

Diabetes Obes Metab. 2005 Jan;7(1):56-64.PMID: 15642076 [PubMed - indexed for MEDLINE]Related articles

Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.

Garber AJ, Clauson P, Pedersen CB, Kølendorf K.

J Am Geriatr Soc. 2007 Nov;55(11):1735-40.PMID: 17979896 [PubMed - indexed for MEDLINE]Related articles

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E.

Diabetes Care. 2003 Mar;26(3):590-6.PMID: 12610006 [PubMed - indexed for MEDLINE]Related articlesFree article

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA.

Diabetologia. 2004 Apr;47(4):622-9.PMID: 15298338 [PubMed - indexed for MEDLINE]Related articles

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles